体外暴露氯法齐明对结核分枝杆菌delamanid和pretomanid耐药有选择性。

IF 4.5 2区医学 Q2 MICROBIOLOGY

Antimicrobial Agents and Chemotherapy Pub Date : 2025-09-22 DOI:10.1128/aac.01113-25

Praharshinie Rupasinghe, Nabila Ismail, Wim Mulders, Robin M Warren, Lavania Joseph, Dumisani Ngcamu, Thabisile Gwala, Shaheed V Omar, Jens Vereecken, Bouke C de Jong, Leen Rigouts, Emanuele Borroni, Daniela M Cirillo, Thomas Schön, Paolo Miotto, Claudio U Köser

{"title":"体外暴露氯法齐明对结核分枝杆菌delamanid和pretomanid耐药有选择性。","authors":"Praharshinie Rupasinghe, Nabila Ismail, Wim Mulders, Robin M Warren, Lavania Joseph, Dumisani Ngcamu, Thabisile Gwala, Shaheed V Omar, Jens Vereecken, Bouke C de Jong, Leen Rigouts, Emanuele Borroni, Daniela M Cirillo, Thomas Schön, Paolo Miotto, Claudio U Köser","doi":"10.1128/aac.01113-25","DOIUrl":null,"url":null,"abstract":"In vitro experiments with Mycobacterium tuberculosis showed that clofazimine exposure selected for delamanid and pretomanid resistance and mutations in fbiA, fbiC, or fbiD-after the acquisition of Rv0678 mutations where this could be determined. Whether this is also possible in vivo and in an Rv0678 wild-type background has to be studied further. Based on the available evidence, however, we propose that nitroimidazole resistance should not be considered an exclusion criterion for the use of clofazimine.","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0111325"},"PeriodicalIF":4.5000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"In vitro exposure to clofazimine can select for delamanid and pretomanid resistance in Mycobacterium tuberculosis.\",\"authors\":\"Praharshinie Rupasinghe, Nabila Ismail, Wim Mulders, Robin M Warren, Lavania Joseph, Dumisani Ngcamu, Thabisile Gwala, Shaheed V Omar, Jens Vereecken, Bouke C de Jong, Leen Rigouts, Emanuele Borroni, Daniela M Cirillo, Thomas Schön, Paolo Miotto, Claudio U Köser\",\"doi\":\"10.1128/aac.01113-25\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In vitro experiments with Mycobacterium tuberculosis showed that clofazimine exposure selected for delamanid and pretomanid resistance and mutations in fbiA, fbiC, or fbiD-after the acquisition of Rv0678 mutations where this could be determined. Whether this is also possible in vivo and in an Rv0678 wild-type background has to be studied further. Based on the available evidence, however, we propose that nitroimidazole resistance should not be considered an exclusion criterion for the use of clofazimine.\",\"PeriodicalId\":8152,\"journal\":{\"name\":\"Antimicrobial Agents and Chemotherapy\",\"volume\":\" \",\"pages\":\"e0111325\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antimicrobial Agents and Chemotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1128/aac.01113-25\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antimicrobial Agents and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1128/aac.01113-25","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

结核分枝杆菌的体外实验表明，氯法齐明暴露选择了delamanid和pretomanid耐药以及fbiA、fbiC或fbid的突变——在获得Rv0678突变后，这可以确定。这在体内和Rv0678野生型背景下是否也可能存在，还需要进一步研究。然而，根据现有证据，我们建议不应将硝基咪唑耐药性作为氯法齐明使用的排除标准。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

In vitro exposure to clofazimine can select for delamanid and pretomanid resistance in Mycobacterium tuberculosis.

In vitro experiments with Mycobacterium tuberculosis showed that clofazimine exposure selected for delamanid and pretomanid resistance and mutations in fbiA, fbiC, or fbiD-after the acquisition of Rv0678 mutations where this could be determined. Whether this is also possible in vivo and in an Rv0678 wild-type background has to be studied further. Based on the available evidence, however, we propose that nitroimidazole resistance should not be considered an exclusion criterion for the use of clofazimine.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Antimicrobial Agents and Chemotherapy 医学-微生物学

CiteScore

10.00

自引率

8.20%

发文量

762

审稿时长

3 months

期刊介绍： Antimicrobial Agents and Chemotherapy (AAC) features interdisciplinary studies that build our understanding of the underlying mechanisms and therapeutic applications of antimicrobial and antiparasitic agents and chemotherapy.